Ilene Ruhoy, and listen to Episode 132 of the Bendy Bodies Podcast
Peripheral Tissue Actors Bimagrumab Bimagrumab is a human monoclonal antibody that binds to the activin type II receptor (ActRII), which inhibits ligands which negatively regulate skeletal muscle growth.177 A single dose of bimagrumab increased lean mass by 2.7% and reduced fat mass by 7.9% at 10 weeks relative to placebo, and improved markers of insulin sensitivity.178 Bimagrumab also led to significant reductions in fat mass, waist circumference, improved lean mass, and reduced hemoglobin A1C
We were unable to record the average length of time each drug was prescribed for, but more than half of each cohort were still on SGLT2i and GLP-1 RA therapy 3 years post initiation
LncRNA ROR promotes NLRP3-mediated cardiomyocyte pyroptosis by upregulating FOXP1 via interactions with PTBP1
A look at conversations taking place on social media around semaglutides would suggest that users understand this
The delayed gastric emptying caused by GLP-1/GIP agonists may theoretically affect the absorption of other medications, though significant clinical impacts with sertraline have not been established
